Targets › MTM1
2 programs from 1 company in 2 trials: 1 Phase 1, 1 Phase 2; Neurology; next expected readout Oct 2027.
Lipid phosphatase which dephosphorylates phosphatidylinositol 3-monophosphate (PI3P) and phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2). Has also been shown to dephosphorylate phosphotyrosine- and phosphoserine-containing peptides. (UniProt, Q13496)
Open in Phaseline: the race on MTM1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Astellas | Resamirigene bilparvovec (AT132) AAV8 vector containing a functional copy of the human MTM1 gene | MTM1 | Phase 2 | X-Linked Myotubular Myopathy | Mar 2030 |
| Astellas | ASP2957 AAV gene therapy delivering MTM1 gene with MHCK7 promoter and MyoAAV3.8 engineered capsid | MTM1 | Phase 1 | X-Linked Myotubular Myopathy | Oct 2027 |
X-Linked Myotubular Myopathy (2)
mixed (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.